StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.36−0.02 (-6.17%)

Close on Nov 17, 2026Market cap $4.67MP/E –Yield –

Lantern Pharma cash

Cash and short-term investments held at the end of each period.

Lantern Pharma's cash was $7.63M at Sep 30, 2026. For fiscal 2025 it was $10.12M, down 57.9% from the year before. The highest annual figure on record is $70.73M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.12M-57.9%
FY2024Dec 31, 2024$24.01M-41.9%
FY2023Dec 31, 2023$41.30M-25.2%
FY2022Dec 31, 2022$55.20M-22.0%
FY2021Dec 31, 2021$70.73M+267.8%
FY2020Dec 31, 2020$19.23M+1460.8%
FY2019Dec 31, 2019$1.23M+176.8%
FY2018Dec 31, 2018$445.16K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$7.63M-38.3%
Q2 FY2026Jun 30, 2026$7.36M-53.7%
Q1 FY2026Mar 31, 2026$6.32M-67.9%
Q4 FY2025Dec 31, 2025$10.12M-57.9%
Q3 FY2025Sep 30, 2025$12.36M-55.9%
Q2 FY2025Jun 30, 2025$15.90M-52.2%
Q1 FY2025Mar 31, 2025$19.72M-48.6%
Q4 FY2024Dec 31, 2024$24.01M-41.9%
Q3 FY2024Sep 30, 2024$28.05M-37.6%
Q2 FY2024Jun 30, 2024$33.26M-30.6%
Q1 FY2024Mar 31, 2024$38.36M-25.6%
Q4 FY2023Dec 31, 2023$41.30M-25.2%
Q3 FY2023Sep 30, 2023$44.93M-22.3%
Q2 FY2023Jun 30, 2023$47.95M-22.8%
Q1 FY2023Mar 31, 2023$51.54M-21.0%
Q4 FY2022Dec 31, 2022$55.20M-22.0%
Q3 FY2022Sep 30, 2022$57.83M-21.7%
Q2 FY2022Jun 30, 2022$62.15M-21.9%
Q1 FY2022Mar 31, 2022$65.22M-19.9%
Q4 FY2021Dec 31, 2021$70.73M+267.8%
Q3 FY2021Sep 30, 2021$73.83M+254.9%
Q2 FY2021Jun 30, 2021$79.59M+234.4%
Q1 FY2021Mar 31, 2021$81.37M+12730.0%
Q4 FY2020Dec 31, 2020$19.23M+1460.8%
Q3 FY2020Sep 30, 2020$20.80M+971.8%
Q2 FY2020Jun 30, 2020$23.80M+1568.8%
Q1 FY2020Mar 31, 2020$634.25K+42.5%
Q4 FY2019Dec 31, 2019$1.23M–
Q3 FY2019Sep 30, 2019$1.94M–
Q2 FY2019Jun 30, 2019$1.43M–
Q4 FY2018Dec 31, 2018$445.16K–

More Lantern Pharma figures

See a number that looks wrong?